Eloxx Pharmaceuticals

Globally renowned Alport syndrome experts will provide key insights Eloxx recently announced achievement of remission in one patient in its Phase 2 Alport syndrome clinical study and…

Data from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney…

<!-- Name:DistributionId Value:8797304 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

WATERTOWN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced the…

Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no…

Strong rationale for development for Alport syndrome as ELOX-02 has demonstrated significant readthrough in COL4A5 nonsense mutations in preclinical studies and is preferentially…

Globally renowned CF Expert, Dr. Eitan Kerem will provide key insights Data from ongoing Phase 2 trials in CF expected in 4Q 2021 WATERTOWN, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) --…

WATERTOWN, Mass., July 06, 2021 (GLOBE NEWSWIRE) --  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) today provided an update on enrollment for the ongoing global Phase 2 clinical program for…